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keratinocytes in the lower layer of the epidermis undergo 
terminal differentiation and transform into corneocytes 
(1). During this differentiation process, lipids are synthe-
sized, stored in lamellar bodies and, at the interface be-
tween the viable epidermis and SC, these lamellar bodies 
are secreted in the intercellular regions (2). The secreted 
lipids form an extracellular lipid matrix crucial for a proper 
skin barrier (3, 4). Three main lipid classes have been iden-
tified: cholesterol, fatty acids, and ceramides. The latter 
constitutes the group of SC lipids that have the most diverse 
chemical structure. Their building blocks are an array of 
sphingoid bases and acyl chains chemically linked together 
by an amide bond, resulting in 16 ceramide subclasses (5). 
Both chains (the sphingoid base and acyl chain) can vary 
substantially in carbon chain length. The composition of 
the SC ceramide fraction (the ceramide profile) has been 
correlated with and shown to be important for lipid organi-
zation and skin barrier function (6–8). In the present 
study, the effect of a ceramide-containing formulation on 
skin barrier recovery, ceramide composition, and lipid or-
ganization were studied.
Through the processes of cornification and desquama-
tion, the SC is continuously rejuvenated (9, 10) and can 
thereby quickly recover the barrier function after disrup-
tion (11). An impaired skin barrier function is encoun-
tered in several inflammatory skin diseases, one of which is 
atopic dermatitis (AD). In AD, an inadequate recovery of 
the impaired skin barrier perpetuates the condition. Nor-
malization of the barrier function in AD is crucial to re-
duce the penetration of irritants and allergens into the 
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Vital functions of the stratum corneum (SC) include 
preventing excessive water loss from the body and pro-
tecting the body from the hostile outside environment by 
acting as an inside-out and an outside-in barrier, respec-
tively. The SC is generated by a dynamic process in which 
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skin. Application of lipophilic formulations that act as an 
additional barrier is a common treatment (12–15). An-
other approach aims at normalization of ceramide compo-
sition (4). Changes in this composition were correlated to 
the reduced skin barrier function in AD (8, 16, 17). Previ-
ously, ceramide-containing formulations have been used to 
study skin barrier repair (18–21) and it was reported that 
the ratios between the three main SC lipids in a formula-
tion was important for short-term recovery (22). Further-
more, it was suggested that long-term application could 
enhance barrier recovery (21). Nonetheless, it is disputed 
whether ceramides in a formulation actually normalize SC 
lipid composition or remain on the skin surface (23). It has 
been shown that the orally administered essential fatty ac-
ids were incorporated in the epidermis (24).
How these formulations accelerate barrier recovery is 
not clearly understood. Therefore, the primary aim of this 
study was to examine how treatment with a formulation 
during barrier recovery affects SC lipid composition and 
subsequently lipid organization. This was done by exam-
ining the normal physiological responses in healthy vol-
unteers. In this study, we applied a ceramide-containing 
formulation based on the composition of the vernix case-
osa (VC). This is a natural ceramide-containing formula-
tion that serves as a protective lipid film covering the fetus 
in the last trimester of pregnancy and during delivery (25). 
Previously, it was shown that VC-like formulations were 
able to significantly accelerate barrier recovery in mice 
(26, 27). This vernix formulation has the advantage that 
ceramides can be formulated into it. The formulation is 
semi-occlusive (28). To examine the effect of the formula-
tion on barrier recovery, we used barrier disruption by tape-
stripping, as this is an effective way to remove the barrier 
and induce barrier recovery in healthy skin (27, 29–32).
Here, it is shown that treatment with the formulation re-
sulted in accelerated barrier recovery of tape-stripped skin 
compared with untreated tape-stripped skin. In regener-
ated untreated SC, an altered ceramide composition was 
observed. These alterations correlated to a decrease in skin 
barrier function. When applying the ceramide-containing 
formulation, the ceramide composition was modulated to-
ward a ceramide composition more closely mimicking that 
of control skin. Combined, these results indicate that bar-
rier disruption induces changes in lipid processing during 
recovery, related to a decreased barrier function and that 
these changes in lipid processing can be modulated by 
application of the VC formulation.
MATERIALS AND METHoDS
Chemicals
The following solvents were used for lipid extraction and analy-
sis: Millipore water (18.2 m), HPLC-grade methanol and chloro-
form from Lab-Scan (Gliwice, Poland), UPLC-grade isopropanol 
and ethanol from Biosolve (Valkenswaard, The Netherlands), 
and HPLC-grade heptane from Actu-All (oss, The Netherlands). 
The synthetic ceramides listed in supplemental Table S1 were 
used as calibrators for the LC/MS analysis. Trypsin and trypsin 
inhibitor for SC isolation were purchased from Sigma-Aldrich 
(Zwijndrecht, The Netherlands).
Clinical study design
The clinical study was approved by the Leiden University Medi-
cal Center Ethical Committee and performed according to the 
Declaration of Helsinki. All volunteers signed an informed con-
sent. Eight female and 7 male Caucasian volunteers, aged 18 to 29 
years (mean age 23 years), were recruited and checked by a der-
matologist. Volunteers were excluded if they had dermatological 
disorders or a history of dermatological disorders, suffered from 
chronic inflammatory diseases, used systemic drug therapies, had 
abundant hair or unnatural abnormalities on the ventral fore-
arms, had a history of drug abuse, or if they were pregnant. All 
enrolled volunteers completed the clinical study.
Figure 1A depicts the timeline of the study. Before the study 
commenced, volunteers had a 1 week washout period in which no 
soaps or cosmetics were applied on the ventral forearms. At time 
point (td0) a site of 3.5 by 2.5 cm of SC was removed at both ventral 
forearms by consecutive tape-stripping using DSquame tape (Cu-
derm, Dallas). The tape-stripping continued until the site ap-
peared shiny (33) and a trans-epidermal water loss (TEWL) of > 
60 g/m2/h was reached (these sites are henceforth referred to as 
stripped). TEWL was measured using AquaFlux AF200 (BIoX, 
London, UK). Thereafter, two fingertip units of a VC-like formu-
lation (composition is shown in supplemental Table S2) were 
applied twice daily for 14 days on one ventral forearm (referred to 
as treated), followed by a 2 day washout period. Treatment alloca-
tion to either left or right arm was alternated between volunteers. 
Figure 1B depicts the four sites investigated in this study: control 
(no treatment, no tape-stripping), treated (treated with formu-
lation), stripped (tape-stripped at tD0), and stripped+treated 
(tape-stripped at TD0 and treated with formulation). At the final 
time point (tD16) 21 tape strips, using polyphenylene sulfide tape 
(Nichiban, Tokyo, Japan), were harvested at all four sites. The 
amount of SC on each tape strip was determined by measuring 
the tape strips with a SquameScan (Heiland Electronic, Wetzlar, 
Germany). Tape-strip zero was discarded. After every other tape 
strip, an infrared spectrum of the tape-stripped skin region was 
made (section 2.5). After tape-stripping, a 4 mm biopsy of both 
recovered sites was collected, near the site where Nichiban tape 
strips were harvested, to perform small angle X-ray diffraction 
(SAXD; see the section by this name below). During the study, 
TEWL of all sites was monitored at distinct time points; measure-
ments were performed before formulation application.
TEWL measurements to determine barrier recovery
To determine barrier recovery of the stripped sites, TEWL was 
monitored. At each time point depicted in Fig. 1C, TEWL was 
measured at three different sections of each site (supplemental 
Figure S1). The barrier recovery percentage was calculated by de-
fining the average of three TEWL measurements at the non-
stripped sites as 100% barrier and TEWL at the stripped sites 
directly after tape-stripping as 0% barrier. The following equation 
was used (26):
( )
( )
= ×
time point
0 (time point)
0 time point
 Recovery %
(TEWL T  –  TEWL T )
100
(TEWL T  –  Average TEWL nonstripped siteT )
 
 
 
For each volunteer, several values were calculated for both the 
treated and untreated stripped sites: i) the recovery percentage of 
the site at three sections at each time-point; ii) the mean of the 
three previous values; iii) the area under the barrier recovery 
curve (AUC) of the means over time, using a point-to-point linear 
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fit; iv) using the same fit, the time it took to reach designated 
recovery percentages between 5 and 100%, with increments of 
5%; and v) the difference in time between the stripped and 
stripped+treated sites at each of the previously mentioned recov-
ery percentage. Recovery percentages >90% were excluded, as 
only 5 volunteers reached these values at both stripped sites, bias-
ing these data.
Quantification of ceramides by LC/MS
Tape-stripped SC can be used to examine the lipid content by 
mass spectrometry (34–36). Samples for ceramide analysis by LC/
MS were prepared from tape-strips 5–8 and 17–20, harvested at 
the four sites on tD16. Samples prepared from tape strips 5–8 and 
17–20 were analyzed separately to determine if the SC ceramide 
composition generated in the initial stage of the recovery process 
(tapes 5–8) was different from that generated in later stages of the 
recovery process (tapes 17–20). Tape strips were punched to an 
area of 2 cm2, extracted, analyzed, and quantified as described in 
Boiten et al. (34). Briefly, a modified four-step Bligh and Dyer 
extraction at 40°C was performed. Extracts were analyzed using 
an Acquity UPLC H-class (Waters, Milford, MA) connected to an 
XEVo TQ-S mass spectrometer (Waters). Separation was per-
formed on a pva-silica column (5 m particles, 100 × 2.1 mm in-
ner diameter; YMC, Kyoto, Japan). Using the calibrators, a 
response model was build and used to quantify the ceramides in 
the analyzed samples. All data were corrected for the cumulative 
SquameScan value (SQ) of the four tape strips comprising the 
corresponding sample. The data resulted in quantitative SC ce-
ramide profiles for each volunteer, at all four sites, and at two 
depths per site. Ceramides are named according to hydrophilic 
head group (subclass) and chain length (e.g., NS C42, ceramide 
subclass NS with a total chain length of 42 carbon atoms) (37). 
For an overview of subclasses and ceramide structures, see supple-
mental Fig. S2.
Quantitative data were used to calculate several parameters. 
Ceramides EoS C66 and NS C40 (supplied in the formulation) 
were excluded from these calculations. The following parameters 
were calculated: i) total amount of the individual subclasses 
(ng/SQ); ii) total amount of ceramides with a total chain 
length 34 carbons (ng/SQ); iii) mean carbon chain length: 
 (       )
    
eachceramide molar amount ceramide carbonchain length
total molar amount all ceramides
×∑ ; and 
iv) percentage of Eo ceramides, as ng Eo/total ng ceramides;
Lateral organization and conformational ordering of SC 
lipids
The lateral organization and conformational ordering of 
the SC lipids were examined by attenuated total reflection Fou-
rier transform infrared spectroscopy (ATR-FTIR). FTIR spectra 
were collected using a Varian 670-IR spectrometer (Agilent 
Technologies, Inc., Santa Clara, CA) equipped with a mercury-
cadmium-telluride detector and an external sample compartment 
containing an ATR accessory (GladiATR, PIKE Technologies, 
Madison, WI) with a single reflection diamond. The sample 
compartment was constantly purged with dry air. Each spec-
trum was an average of 150 scans, with a spectral resolution of 
2 cm1. Conformational ordering of the lipids was determined 
using the center of gravity of the peak of the CH2 symmetric 
stretching vibrations at 90% of the peak height. The bandwidth 
from the second derivative of the CH2 scissoring region was se-
lected as a measure for lateral packing of the lipids and deter-
mined as described previously (38, 39). CH2 stretching vibration 
peak position values <2850 cm1 indicate an ordered phase, 
whereas values above 2852 cm1 indicate a high degree of disor-
dering, being a liquid phase. The second derivative of the CH2 
scissoring region was baseline-corrected between the endpoints 
of the scissoring region (1460–1480 cm1) and the full width 
at half maximum (FWHM) was calculated (39). Values of 5 
spectra (tape 2–10 and tape 12–20) per site per volunteer were 
used for the analyses.
SAXD
SC isolated from biopsies harvested at stripped and stripped+ 
treated sites were examined by SAXD. SAXD was used to deter-
mine the SC lipids lamellar organization. To isolate SC for SAXD 
analysis, biopsies were placed overnight in a 0.1% trypsin solu-
tion in PBS at 4°C, followed by 1 h incubation at 37°C. The SC 
was peeled off and washed in 0.1% trypsin inhibitor solution in 
PBS and twice in Millipore water. Dried SC sheets were stored 
under argon and over silica gel until use. All SAXD measurements 
were performed at the European Synchrotron Radiation Facility 
(Grenoble, France) at station BM26B. SAXD patterns were col-
lected on a Pilatus 1M detector at room temperature for 5 min. 
The sample-to-detector distance was 2 m. Prior to data collection, 
the SC samples were hydrated over a 27% (w/v) NaBr solution 
for 24 h at room temperature. The scattering intensity I (arbitrary 
units) was measured as a function of the scattering vector q (in 
Fig. 1. Study design. A: Timeline of the clinical study (Time points are indicated as t with days as subscripts). Volunteers were first screened 
by a dermatologist (tD-7), followed by a 1-week washout period. At tD0 the SC was removed by tape-stripping. The formulation was applied two 
times daily for 2 weeks followed by 2 days washout. The activities and measurements are indicated at each time point (tD-7 to tD16). At all indi-
cated time points, TEWL was measured, except for tD-7. B: The studied sites on the ventral forearms. on both arms, one site was tape-stripped; 
on one arm, formulation was applied. C: The time points at which TEWL was measured to monitor barrier recovery of the stripped sites.
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nm1), defined as: 
pi θ
λ
4 sin( )
q=
, in which  is the scattering angle 
and  is the wavelength. From the position of the main peak (re-
ferred to as peak 2 with position q2), the spacing (d) of the lipid 
lamellae was calculated using d pi2 
q2
= . As in SC, this peak position 
is determined by the structure of the two lamellar phases; a 
change in the spacing indicates a change in these lamellar phases 
(8).
Software and statistical analysis
All LC/MS data were processed using MassLynx and Target-
Lynx software (V4.1 SCN 843, Waters Inc.). FTIR data were 
processed and analyzed using Resolutions Pro 4.1 (Agilent Tech-
nologies, Inc.). Principal component analysis (PCA) is a com-
monly used analysis of lipidomics data sets (40, 41). It is a 
mathematical dimensional reduction that can effectively visualize 
variation and the difference between samples in large data sets by 
reducing all variables to principal components (PCs). PCA was 
performed using Multibase add-in for Excel (NumericalDynam-
ics.Com). For PCA, the quantitative data obtained from the ce-
ramide analyses were normalized to the total amount of cerami des 
in the samples. The four individual sites (control, treated, stripped, 
and stripped+treated) of each volunteer were defined as “PCA 
samples”. All quantified ceramides at both depths were defined as 
variables of that PCA sample (total of 584 variables), thereafter 
the mean of each ceramide/variable in all PCA samples was cen-
tered at zero (subtracting the mean).
Correlation analysis and point-to-points fits were performed us-
ing GraphPad Prism (V6.05, Graphpad). Group-wise comparisons 
were performed using linear mixed models (LMMs) in SPSS (V24 
IBM). All measurements within the same subject were treated as 
repeated measurement. LMMs were used because these models 
have the advantage that the effect size of individual variables and 
their interactions can be examined, and they can handle missing 
data (42). Supplemental Fig. S3 explains how the LMMs were 
used here. All interactions between fixed variables were included 
in the first run of a model and when nonsignificants (P > 0.05) 
were taken out one by one. Significance levels are indicated 
as followed: * (P < 0.05), ** (P < 0.01), *** (P < 0.005), and 
**** (P < 0.001).
RESULTS
Barrier recovery in healthy volunteers
To determine the effect of the formulation on barrier 
recovery, changes in skin barrier over time (measured as 
TEWL and expressed as recovery percentage) were exam-
ined. Figure 2A shows a typical example of barrier recovery 
percentage as function of time for untreated and treated 
stripped sites of one volunteer. After 16 days, all volunteers 
had reached a recovery % >85 at both sites. For each volun-
teer, the AUC was calculated of both the untreated and 
treated stripped sites (Fig. 2B). A larger AUC implies less 
barrier dysfunction during the 16 days. Treatment with the 
formulation significant increased the AUC, indicating in-
creased recovery.
However, the AUC does not take into account the kinet-
ics of the recovery process. To determine whether treat-
ment accelerated barrier recovery, differences in time 
between untreated and treated stripped sites were exam-
ined at multiple designated recovery percentages (t in 
Fig. 2A). Figure 2C depicts the median and interquartile 
range of t at different recovery percentages for all volun-
teers. A median of zero would indicate no change in recov-
ery time due to treatment. A positive deviation from zero 
was observed at almost all recovery percentages with a 
spike at 25% and a steady increase above 50%. Treatment 
significantly accelerated barrier recovery ending with a >2 
days faster median recovery. For control, both the AUC 
and the t were tested for correlation to the TEWL di-
rectly after tape-stripping (supplemental Table S3). No 
correlations were observed, indicating that these param-
eters were not dependent on the amount of barrier 
disruption.
Principle component analysis of ceramide profiles
To gain insight into differences between the ceramide 
profiles of the four different sites, PCA was performed 
on the quantitative ceramide data. Figure 3A depicts the 
Fig. 2. The effect of treatment on barrier recovery. A: The typical elapse of barrier recovery over time for untreated and treated stripped 
sites for a single volunteer. Points are means (±SD) of three measurements within one site. Lines are point-to-point connections. The dotted 
line indicated the difference in time (t) between the untreated and treated curve at a designated recovery percentage. B: The AUCs/1000 
for all volunteers. Lines connect data points of the same volunteer. A paired t-test showed significant increase at the treated sites. C: The t 
for all volunteers at recovery percentages between 5 and 90%. The data were nonnormally distributed and are shown as median and inter-
quartile range. Deviations from zero were tested with a Wilcoxon signed-rank test.
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variable loadings, indicating how strongly each variable 
(ceramides detected in the samples) correlated to PC1 and 
PC2. If the value is higher (deviates from center of the 
graph in x or y position), it has contributed more to the 
variation explained by PC1 or PC2, respectively. The 10 
variables with the highest correlation coefficients are indi-
cated in the plot. PC1 and PC2 explained a total inertia 
(variance) of 66.3%. Figure 3B shows the plot of the PCA 
samples, depicting the PC1 and PC2 scores of each PCA 
sample. Samples were assigned to clusters corresponding 
to the four sites indicated by different colors. Separation 
between clusters was observed, demonstrating that varia-
tion between the ceramide profiles corresponded to varia-
tion between samples of different sites. Therefore, changes 
in ceramide profile due to treatment and tape-stripping 
can be explained by the variable loadings of the PCs.
Clusters of treated sites were separated from untreated 
sites as depicted in Fig. 3B. By examining plot 3A it can be 
seen that this was primarily due to four variables. These 
variables corresponded to the two formulated ceramides 
(NS C40 and EoS C66) detected in samples of both depths. 
The PCA demonstrated that a large part of the variation in 
the ceramide profiles was due to the two ceramides in the 
formulation. The increase due to formulation application 
of these naturally occurring ceramides was examined. Sup-
plemental Fig. S4 shows that the amount at treated sites was 
increased at both tape-stripping depths. An LMM of the 
logarithm of these amounts confirmed these observations 
(supplemental Table S4).
Next, separation of clusters corresponding to stripped 
and nonstripped sites was investigated. Variables correlat-
ing strongly to PC2 were primarily responsible for the ob-
served separation (supplemental Fig. S5 shows a complete 
graphic overview of the PC2 loadings). When examining 
the loadings of PC2, highly positive correlations were ob-
served for ceramides of subclass AS and, to a lesser extent, 
ceramides for subclass NS. Highly negative correlations 
were observed for ceramides from subclass NP. Changes in 
ceramide profile were observed between the different sites. 
In the next section, the results of the PCA were used as 
leads to investigate whether these changes correlated to 
changes in barrier function and the recovery process.
Correlations between ceramide profile and barrier 
function
To investigate whether barrier function correlated to 
changes in SC ceramide profile, changes in ceramides AS 
and NS, identified by PCA, were correlated to the TEWL at 
Td16 (supplemental Fig. S6 shows the TEWL at tD16). 
Figure 4A and B depicts these correlations for the total 
amount of subclass AS. At both depths, a significant posi-
tive correlation between the amount of subclass AS and 
TEWL was observed. This illustrates that an increase in sub-
class AS correlated with reduced skin barrier function. Next, 
it was examined whether stripping, treatment, SC depth, or 
the interaction between these conditions had an effect on 
the amount of subclass AS, using an LMM. The model used 
stripped, treated, and depth as fixed factors and subject as 
a random factor. Table 1 depicts the effect sizes obtained 
with the model. Figure 4C depicts the mean (±SD) of the 
amount of subclass AS measured at all four sites at both 
depths. Using the model, it was determined that subclass 
AS increased significantly at stripped sites. Treatment or 
depth alone showed no significant effects compared with 
the control. However, at the stripped site, treatment did 
have a significant effect. The interaction stripped*treated 
in Table 1 illustrates this effect. When subjected to strip-
ping and treatment, the amount of AS changed by the ef-
fect sizes of stripped and treatment; in addition to both 
effects, the interaction term stripped*treated is added. At 
stripped+treated sites, treatment significantly reduced the 
increase in AS observed due to stripping with 81.2 ng/SQ 
(treatment + stripped*treated). Similar results were ob-
tained when examining NS C44 (supplemental Fig. S7 and 
Table 1). It was decided not to use the total amount of sub-
class NS, as this value was influenced by ceramide NS C40 
in the formulation. NS C44 was the most abundantly pres-
ent of the NS ceramide subclass members and was chosen 
as a proper representative of subclass NS.
Besides subclasses, ceramide chain lengths, especially ce-
ramides with a total carbon chain length of 34 carbons 
(C34), are known to correlate to barrier dysfunction (17). 
Here, a significant positive correlation was observed be-
tween the total amount of C34 ceramides (sum of the 
amounts of NdS, NS, NP, NH, AdS, AS, AP, and AH with a 
total of 34 carbons) and TEWL, at both depths (Fig. 4D, E), 
demonstrating that higher levels of C34 ceramides corre-
lated with reduced barrier function at day 16. A similar 
LMM as that of subclass AS and NS 44 was built for C34 
ceramides (Table 1). The total amount of C34 ceramides at 
the four sites at two depths was plotted as the mean ± SD in 
Fig. 4F. By using the model, a significant increase at the 
stripped sites was observed. Comparable to subclass AS, 
treatment only significantly affected the stripped+treated 
Fig. 3. PCA of all SC ceramides and the amount of 
ceramides NS C40 and EoS C66. A: The PCA loading 
plot. Inertia per PC is indicted as percent variation. 
Variables are all ceramides quantified in samples ob-
tained from tape-strips 5–8 and 17–20; the latter are 
indicated with a 2 after the subclass name. B: A plot of 
the PCA samples (the four sites of all volunteers). The 
samples were clustered per site.
 at W
alaeus Library / BIN 299, on M
arch 28, 2018
w
w
w
.jlr.org
D
ow
nloaded from
 
.html 
http://www.jlr.org/content/suppl/2017/12/07/jlr.M079186.DC1
Supplemental Material can be found at:
Treatment enhances barrier repair and changes lipid profile 255
sites. Treatment reduced the increase in C34 ceramides 
with 31.6 ng/SQ compared with stripped sites.
Next, the correlation of each subclass to TEWL was ex-
amined (Fig. 4G: Pearson r for each subclass). This correla-
tion underlined the observations with PCA, where subclass 
NS and AS had a positive correlation and subclass NP a 
negative correlation to PC2. Both subclasses NS and AS 
have a distinct synthesis route different from subclasses NP 
and AP; this suggested a ratio dividing the subclasses as fol-
lows: + + + + +
+
NdS NP NH AdS AP AH
NS AS
. This ratio correlated 
to TEWL (Fig. 4G) even for the samples of each site inde-
pendently. Together, these data showed that i) barrier 
function correlated to the ratio of ceramide subclasses from 
different synthesis routes, ii) certain ceramide subgroups 
were increased in stripped SC, iii) the amount of these sub-
groups correlated to TEWL, and iv) treatment was able to 
reduce the increase of these ceramide subgroups that cor-
relate positively to an increased TEWL (AS, NS 44, and C34 
ceramides).
Mean carbon chain length and spacing related to the 
lamellar phases
Previous studies have shown that the main ceramide 
chain length is an important parameter of the SC ceramide 
fraction (43). For this reason, it was decided to study 
whether a correlation existed between mean chain length 
and both the Eo ceramide fraction and lamellar spacing. 
Figure 5A shows the mean chain length of the ceramides in 
samples prepared from tapes 5–8 and 17–20. A similar 
Fig. 4. The effect of treatment on ceramide groups correlating to barrier function. A, B: Correlations between TEWL and the amount of 
subclass AS (ng/SQ). The Pearson r and P are indicated (A: Samples of tape-strips 5–8; B: Samples of tape-strips 17–20). C: The amount 
subclass AS (ng/SQ) at all sites at depths of both 5–8 and 17–20 tape-strips (mean ± SD). Effect size was determined with an LMM. D, E: 
Correlations between TEWL and the amount of ceramides with a chain length of 34 carbon atoms (ng/SQ). The Pearson r and P are indi-
cated (D: Samples of tape-strips 5–8; E: Samples of tape-strips 17–20). F: The amount of ceramides with a chain length of 34 carbon atoms 
(ng/SQ) at all sites at depths of both 5–8 and 17–20 tape-strips (mean ±SD). Effect size was determined with a linear mixed model. G: Pearson 
r of the correlation between TEWL and the total amount of each subclass at all sites at depths of both 5–8 and 17–20 tape-strips. H: The cor-
relation between TEWL and ratio of subclasses NdS + NP + NH + AdS + AP + AH
NS + AS
 of both depths, excluding NS C40. Pearson r per site were: 
control, 0.648; stripped, 0.808; treated,0.729; and stripped+treated, 0.694. All statistical outputs of the LMM are found in Table 1.
TABLE 1. The output of the LMMs per ceramide subgroup
Subclass AS Ceramide NS C44 C34 ceramides
Estimate P Estimate P Estimate P
Intercept (control) 267.1 <0.001 56.6 <0.001 39.4 <0.001
Effect size Stripped +281.5 <0.001 +56.4 <0.001 +68.0 <0.001
Treated +27.3 0.403 +7.2 0.194 +5.6 0.438
Depth 17-20 41.3 0.076 2.1 0.597 5.2 0.297
Interactions Stripped*Treated 108.5 0.020 19.5 0.013 37.2 <0.001
The intercept is the estimated amount at the control site at a depth of the 5–8 tape-strips. Estimates are in ng/SQ. 
The effect size is the amount in ng/SQ with which the variable changes the intercept. Significance levels of all effect 
sizes and interaction are given.
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LMM as for subclass AS was made (Table 2). This showed 
that stripping decreased the mean chain length significantly. 
Treatment was able to increase the mean chain length, re-
storing the mean chain length at the stripped+treated sites. 
The increase in mean chain length of the stripped+treated 
sites could be due to an increase in the fraction of esteri-
fied omega-acyl-ceramide (Eo fraction) (supplemental 
Fig. S8 shows this correlation per site). Changes in Eo frac-
tion due to treatment of the stripped site (stripped  
stripped+treated) correlated to changes in the mean chain 
length due to treatment of the stripped site (Fig. 5B). Treat-
ment was able to increase the Eo fraction significantly 
(Fig. 5C and Table 2 show the Eo fraction and the output 
of LMM, respectively).
The carbon chain length of the ceramides could influence 
the spacing of the strong diffraction peak in the diffraction 
pattern as measured by SAXD. From the position of the 
strong diffraction peak in the X-ray diffraction curve (peak 2), 
the corresponding spacing was calculated (referred to as 
peak 2 in Fig. 5D). A significant increase in spacing due to 
treatment was observed and a positive correlation was ob-
served between the mean chain length and the spacing 
(Fig. 5E). When comparing the spacing to TEWL, a corre-
lation was observed between an increased TEWL and a de-
crease in spacing (Fig. 5F). Stripping and treatment thus 
affected the mean chain length, which correlated to Eo 
fraction and the lamellar spacing.
Effects of stripping and treatment on lateral packing
Next to lamellar spacing, lateral packing is important 
for a proper barrier function. For this reason, the effect 
of treatment and stripping on lateral packing was also 
Fig. 5. Mean chain length and lamellar spacing. A: The mean total chain length (carbon atoms) for the four different sites at two depths 
excluding the ceramides of the formulation in the calculation. Data were compared using an LMM. B: The correlation between changes in 
fraction Eo ceramides and changes in the mean chain lengths (carbon atoms) at the stripped site due to treatment (amount at the stripped 
site subtracting the stripped+treated). C: The Eo fraction of the samples at the four different sites at two depths. Data were compared using 
an LMM. D: The difference between the SAXD peak 2 position in the stripped and stripped+treated sites. The differences were tested with 
a Wilcoxon matched pairs signed rank test. E: The correlation between the SAXD peak 2 (nm) and TEWL (g/m2/h) at the end of the study. 
Pearson r and P are provided. F: The correlation between the SAXD peak 2 (nm) and the mean chain length (carbon atoms) of all cerami-
des. Pearson r and P are provided. G. The wavenumber in cm1 of the stretching peak position. Data were compared using an LMM.
TABLE 2. The output of the LLMs for mean chain length, Eo fraction, and stretching peak position. 
Mean chain length Eo fraction Wavenumber cm1
Estimate p-value Estimate p-value Estimate p-value
Intercept 46.76 <0.001 0.107 <0.001 2848.60 <0.001
Effect size Stripped 0.37 <0.001 +0.011 0.007 +0.02 0.622
Treated +0.33 <0.001 +0.014 <0.001 +0.09 0.013
Depth +0.08 0.366 +0.003 0.537 0.17 <0.001
Interactions Stripped*depth +0.29 0.021 +0.012 0.043 +0.26 <0.001
The mean chain length and Eo fraction were calculated excluding ceramides NS C44 and EoS C66. The the 
wavenumber in cm1 of the stretching peak position was calculated using the center of gravity at 90% peak height. 
As fixed factors stripped, treated, and depth were used. The intercept was the control site at a depth of 5–8 tape-strips 
or for spectra of tapes 2–10.
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examined. All skin sites were studied using ATR-FTIR, 
where both the CH2 symmetric stretching vibrations and 
the CH2 scissoring vibrations were examined. An LMM was 
built for the CH2 symmetric stretching peaks. Stripped, 
treated, and depth were used as fixed factors and subject as 
random factor (Table 2). A significant increase in peak po-
sition was observed due to barrier disruption and treat-
ment, suggesting a slight increase in disordering of the 
lipids. The effects were stronger deeper in the SC. How-
ever, the peak position at all sites was located at wavenum-
bers between 2848.46 cm1 and 2848.80 cm1, indicating 
an ordered lateral lipid organization at all sites. A similar 
LMM was built for the CH2 scissoring peak. We determined 
the FWHM of the scissoring vibrations. Supplemental Ta-
ble S5 depicts the result of this model. At the control site 
the FWHM was significantly decreased at deeper layers 
(tape-strips 12–20); yet, the FWHM was 11.3 cm1 or 
higher, indicative of a large fraction of lipids forming an 
orthorhombic lateral packing. No deviation from an or-
dered structure by treatment or stripping was observed.
DISCUSSIoN
In this study, we showed that a VC-based formulation 
is able to accelerate the barrier recovery of tape-strip- 
disrupted healthy human skin and, for the first time, dem-
onstrate that formulations can act by normalizing the SC 
lipid composition. Multiple effects of barrier disruption 
and treatment on barrier recovery, ceramide composition, 
and lipid organization were examined (Fig. 6 provides an 
overview). Using PCA, samples were clustered into groups 
of treatment and stripping based on changes in ceramide 
profile. Moreover, correlations of ceramide levels to PC2 
had great similarities to correlations between ceramide lev-
els and barrier function after barrier recovery. Thus, the 
loading variables for PC2 were a powerful tool to identify 
ceramides responsible for profile changes related to bar-
rier disruption. At the stripped sites after recovery, multiple 
changes in the ceramide profiles were observed. Treat-
ment partially normalized these changes in SC ceramide 
composition caused by barrier disruption. These ceramide 
profile changes correlated to the barrier function, indicat-
ing a relation of the changes in these lipids and an acceler-
ated barrier recovery process.
When examining barrier recovery, two phases could be 
distinguished; a first steep increase in barrier recovery per-
centage after 3 h followed by second gradually diminishing 
barrier recovery rate. Treatment increased the level of the 
first phase, where after 3 h, a recovery of 25% was reached 
compared with 10% without treatment. However, early 
effects of formulation on barrier recovery measured by 
TEWL could be caused by leftover formulation on the skin 
(27), even though leftover formulation was removed prior 
to TEWL measurement. The second recovery phase was 
not affected by residual formulation on the skin surface 
because the formulation was applied after TEWL measure-
ment. During the second phase, treatment had a pro-
nounced effect on the barrier recovery rate.
one of the aims of applying the tested formulation was 
to replenish SC ceramides. Treatment caused significant 
increase in the formulated ceramide level, even at deeper 
SC layers. Although a 2-day washout period would have re-
moved almost all superficial formulation, it cannot be 
stated with 100% certainty that the applied ceramides mea-
sured with LC/MS were incorporated into the SC. Some 
formulated ceramides could still be present in folds of the 
SC. In cultured skin, it was shown that ceramides stay in 
these folds (23). Although the increase of the formulated 
ceramides was observed at both depths, tape strips ob-
tained lipid material from various depths of SC (44) and, 
thus, tape strips at both depths can contain material from 
these folds. Nevertheless, it has been demonstrated that 
when treating stripped ex vivo SC with deuterated ce-
ramides once, small ceramide amounts were incorpo-
rated into the SC lipid matrix after regeneration (Topically 
applied ceramides interact with the stratum corneum lipid 
matrix in compromised skin.,Pharm. Res, Berkers T., Viss-
cher D, Gooris G.S., Bouwstra J.A.). others have shown 
that dimeric ceramides are able to diffuse into the skin 
(45). Together with the relatively large increases of the for-
mulated ceramides, it is likely that a fraction of the applied 
ceramides did incorporate into the SC lipid matrix and ac-
tively enhanced barrier recovery.
Multiple studies have used SC lipid-containing formula-
tions, either for long- or short-term treatment (18–21) and 
it has been shown that the SC lipids ratio in formulations is 
Fig. 6. An overview of the effects of barrier disruption and treat-
ment. Negative effects are indicated with a  sign and positive ef-
fects with a + sign. Barrier disruption induces barrier recovery and 
treatment accelerates this process. Changes in the Eo fraction, 
mean chain length, and lamellar spacing showed correlations (cor) 
indicated by the arrows. The changes in lipid composition, organi-
zation, and subsequent effects are indicated. The ratio dS + P +H
S
 is 
mainly determined by the enzymes human-dihydro-4-desaturate 
(DES1) and human-sphingolipid-C4-hydroxylase (DES2), responsi-
ble for the production of sphingosine and phytosphingosine 
ceramides from dihydrosphingosine ceramides, respectively. The 
arrows indicate that barrier disruption changed the lipid synthesis 
decreasing this ratio and treatment had the opposite effect. The 
correlation of the TEWL at day 16(d16) to the subclass ratio is indi-
cated; however, the amount of C34 and the SAXD Peak 2 position 
correlated to TEWL as well.
 at W
alaeus Library / BIN 299, on M
arch 28, 2018
w
w
w
.jlr.org
D
ow
nloaded from
 
.html 
http://www.jlr.org/content/suppl/2017/12/07/jlr.M079186.DC1
Supplemental Material can be found at:
258 Journal of Lipid Research Volume 59, 2018
essential for short-term barrier recovery (22, 46). Visscher 
et al. (28) tested the effect of 5 days VC treatment on TEWL 
and hydration of tape-stripped SC, but they observed no 
changes in TEWL when comparing with untreated stripped 
SC. In comparison to our study, the barrier was less exten-
sively disrupted. Therefore, incomplete SC removal may 
lead to a lower efficacy of the formulation to improve bar-
rier repair. Here, a detailed description of the recovery 
process is provided and, for the first time, insights are given 
into changes in the SC ceramide composition due to treat-
ment. Below, a mechanism is suggested on how a VC-based 
formulation affects ceramide synthesis.
At the stripped (nontreated) sites, two prominent changes 
were observed in the endogenous ceramides: i) the amounts 
of S subclass were increased and ii) C34 ceramides were 
increased. The amounts of these ceramide groups correlated 
to a decrease in barrier function. However, from these 
data, it could not yet be deduced whether these increases 
were causal or contingent with a decreased barrier function. 
A plausible reasoning is that in a direct response to barrier 
disruption, the epidermal calcium gradient changed (2) 
and a subsequent modulation in gene expression occurred 
(29). These changes in epidermal homeostasis might have 
affected the SC ceramide processing in two ways.
First, in epidermal lipid biosynthesis, ceramides contain-
ing a dihydrosphingosine are either converted into sphin-
gosine- or phytosphingosine-containing ceramide (47, 48) 
(Fig. 6) (biosynthesis of subclass H ceramides has not yet 
been reported). When defining the ratio between the sub-
classes as + +dS P H
S
, this ratio could only change if either 
of the two known lipid biosynthesis pathways changed. The 
present study showed that this ratio was substantially de-
creased at the stripped sites, indicating barrier disruption 
influenced the specific synthesis pathways of subclasses S 
and P. Importantly, the ratio between the subclasses cor-
related strongly to TEWL after barrier recovery, which sug-
gests that an optimal ratio is important for an optimal 
skin barrier repair. Furthermore, this correlation was 
site independent; thus, at stripped sites with a higher 
TEWL, synthesis of sphingosine ceramides was preferred 
over phytosphingosine-containing ceramides. Treatment 
was able to favorably change the subclass ratio toward a 
lipid composition that correlated to a more efficient skin 
barrier recovery by reducing the amount of NS and AS 
subclasses.
The second change in lipid biosynthesis due to barrier 
disruption was the increased amount of C34 ceramide. 
These ceramides are produced from the sphingoid and 
acyl building blocks [a C16 or C18 acyl chain and a C16 or 
C18 sphingoid chain (49)] and do not require additional 
elongation steps (50). Although these C34 ceramides 
can be produced as a quick first response to mitigate an 
impaired SC barrier, C34 ceramides are “short” chain ce-
ramides, which have been shown to reduce skin barrier 
function (6, 51).
Altogether, the C34 ceramides and the ratio of ceramide 
subclasses could function as indicators of reduced barrier 
function and changes in barrier lipid homeostasis. Here, 
we showed that treatment was able to partly diminish the 
amount of C34 ceramides and, by diminishing the amount 
of NS and AS, able to change the subclass ratio and thus 
the preceding ceramide synthesis. These changes could be 
attributed to i) the semi-occlusive effect of the formulation, 
in which the formulation acted as an additional barrier, or ii) 
the presence of excess formulated ceramides reducing the 
response to replenish the ceramides. As a whole, these data 
show that the formulation partially normalized the lipid 
biosynthesis and directed the SC toward a more functional 
lipid homeostasis. The lipid organization was used to verify 
that changes in ceramide composition were causal to changes 
in barrier function.
An important characteristic of the SC ceramide fraction 
is the mean chain length. The chain length was reduced 
when the barrier function is impaired, for example, in 
stripped sites and AD (8, 17). Here, treatment was able to 
restore the mean chain length at stripped sites (excluding 
the added ceramides). The mean chain length correlated 
strongly to the fraction of Eo ceramides and treatment 
was able to increase the Eo fraction. At the treated sites, 
the spacing was slightly increased, indicating an increase 
in the repeat distances of the lamellar phases. Further-
more, the spacing correlated to the mean chain length 
and weakly correlated to the Eo fraction (data not shown). 
Taken together, the data suggest that treatment influenced 
the lamellar lipid organization through increasing the 
Eo fraction, thereby increasing the mean change length 
(Fig. 6).
As far as lateral packing was concerned, our studies 
showed that a high fraction of lipids formed an orthorhom-
bic packing and this was not affected by stripping. For this 
reason, the fraction of lipids forming an orthorhombic 
packing could not be increased due to treatment. Changes 
due to treatment might become more apparent in affected 
skin of AD patients where the fraction of lipids forming an 
orthorhombic organization is decreased compared with 
that in healthy skin (43).
To summarize the effects of the VC based formulation 
on barrier recovery in healthy SC, it was observed that treat-
ment: i) accelerated barrier recovery, ii) changed the lipid 
synthesis to a more favorable lipid composition by decreas-
ing the amount of C34 ceramides and changing the sub-
class ratio + +dS P H
S
 and increasing the fraction of Eo 
ceramides, and iii) these changes in lipid composition af-
fected the SC lipid organization and correlated to the SC 
barrier function. Interestingly, similar increases in S sub-
class and increases in the fraction of C34 chain length 
ceramides were observed in AD (8, 17). An essential 
application of this formulation could be in a particular 
group of AD patients, where barrier-restoring lipophilic 
formulations are commonly used (52). Moreover, the treat-
ment presented here modulated the alterations in lipid 
composition observed in AD toward a healthy lipid homeo-
stasis.
The authors would like to thank Evonik industries AG for 
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